## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.1% below STRENGTH zone (3.0-6.0%); PEG 1.97 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($190.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Cardinal Health (CAH) Stock Pulls Back From Record Highs: Latest News, Forecasts and Investment Outlook as of December 3, 2025**
- Source: ts2.tech | 20251203T230739 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health (CAH) stock has experienced a pullback after a significant rally in 2025, with shares down 2.64% on December 3, 2025. Despite this recent weakness, the company has delivered strong year-to-date returns and robust Q1 FY 2026 results, driven by specialty pharmaceuticals and strategic acquisitions like Solaris Health. Analyst sentiment remains largely positive with "Buy" ratings and target price increases, though valuation concerns and execution risks are noted by more cautious investors, suggesting a potential consolidation phase for the stock.

**2. Key facts: Cardinal Health prioritizes high ROI; officers surrender shares**
- Source: TradingView | 20251203T210623 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health (CAH) focuses its capital deployment strategy on high return on investment opportunities, emphasizing shareholder returns and strategic mergers and acquisitions. Recently, on December 2, 2025, company officers surrendered 1,949 shares to cover costs associated with exercising options and tax liabilities, as reported to the SEC.

**3. What Recent Specialty Pharma Moves Mean for Cardinal Healthâ€™s Stock Valuation**
- Source: Sahm | 20251203T111142 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health's stock has seen significant growth, climbing 76.2% year-to-date, driven by its expansion into specialty pharmaceuticals and distribution partnerships. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 55%, its current Price-to-Earnings (PE) ratio of 31x is slightly above its fair level of 29.4x, indicating that the valuation is "about right" given its financial profile and future potential. The article encourages investors to use "Narratives" to customize valuation models based on their own assumptions about the company's future.

**4. Cardinal Health, Inc. $CAH Position Increased by OMERS ADMINISTRATION Corp**
- Source: MarketBeat | 20251204T083653 | Bullish | Relevance: 100%
- OMERS ADMINISTRATION Corp significantly increased its stake in Cardinal Health (NYSE:CAH) by 130% to 20,345 shares, valued at approximately $3.42 million. This move is part of a broader trend of institutional investors boosting their positions in the company, with overall institutional ownership reaching about 87.17%. Cardinal Health recently surpassed Q3 earnings expectations with an EPS of $2.55 and revenue of $64.01 billion, leading analysts to issue a "Moderate Buy" consensus and raise price targets.

**5. Pinkerton Wealth LLC Buys New Stake in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251204T020904 | Bullish | Relevance: 100%
- Pinkerton Wealth LLC has acquired a new stake in Cardinal Health, Inc. (NYSE:CAH), purchasing 12,031 shares valued at approximately $2.02 million during the second quarter. This move is part of broader institutional interest, with 87.17% of CAH stock now held by hedge funds and other institutional investors. Wall Street analysts maintain a "Moderate Buy" rating for Cardinal Health, noting its strong quarterly performance, positive FY2026 EPS guidance, and a recently declared dividend.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-05 | Wells Fargo | $221 | $185 | +19% |
| 2025-11-04 | Mizuho | $210 | $170 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-05 | Wells Fargo | main | Overweight |
| 2025-11-04 | Mizuho | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.97 elevated, pricing in significant growth expectations. Analyst sentiment positive (2 raises, avg +21%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.5B |
| Beta | 0.64 |
| 52W Range | $117.53 - $214.93 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.97 |
| Forward P/E | 18.0 |
| Current P/E | 20.3 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.3% to -6.1% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.1pp (needs >3.0% for momentum thesis). Underperforming sector by 4.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.28x) but short-term weakness (below SMA20). MACD histogram bearish (-2.79), momentum weakening. RSI neutral at 52. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.14% (CS: 3) | Weak |
| RSI_14 | 52.3 | Neutral |
| MACD Histogram | -2.79 | Bearish |
| vs SMA20 | 0.965x | Below |
| vs SMA50 | 1.104x | Above |
| vs SMA200 | 1.280x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $199.19
- **Stop Loss:** $190.15 (4.5% risk)
- **Target:** $208.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 55
- **Position Value:** $10,955.45
- **Portfolio %:** 10.96%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*